Endo Pharmaceuticals Holdings News

CHANGE IN RATINGS Apple initiated at Calyon Securities with a Buy rating and $260 price target.

An Oppenheimer analyst downgraded shares of Endo Pharmaceuticals Holdings Inc. Monday, pointing to regulatory delays for two of Endo's testosterone drug candidates.

Drug stocks gained ground Thursday afternoon while shares of Endo Pharmaceuticals fell on news that U.S. regulators have declined to approve its hormone therapy Aveed for the treatment of low testosterone in men.

The NYSE Arca Pharmaceutical Index /quotes/comstock/10t!drg.x was up 0.4% to 313.26 and the NYSE Arca Biotechnology Index /quotes/comstock/10t!btk.x climbed 0.6% to 916.22. Endo shares were off 5% at $21.30. /quotes/comstock/15*!endp /quotes/nls/endp Endo Pharmaceuticals... /marketstate/country/ The market is open The market is closed $ 21.02 ...

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration regarding the New Drug Application for its extended-duration testosterone undecanoate injection, AVEED , for men diagnosed with low testosterone.

Historically, playing the drug makers in December has proven to be a safe bet. December ranks first, above August and September, as the best performing month for the iShares Nasdaq Biotechnology ETF with average gains of about 8%. Outlined below is a defensive game plan that might help investors beat the benchmark.

David Holveck, in his first full year as CEO of Endo Pharmaceuticals , has overseen the company's purchase of one drug company and signed two licensing agreements in three deals with a combined value of more than $900 million.

King Pharmaceuticals Inc., LifePoint Hospitals Inc. and Endo Pharmaceuticals Holdings Inc.

Biotech 2009, the annual conference co-hosted by Pennsylvania Bio and BIO NJ, will take place Monday and Tuesday and feature keynote speakers David Holveck and Fred Hassan.

CHADDS FORD,A Pa. Generic drug maker Endo Pharmaceuticals has reached a settlement with the manufacturer of a pain drug, Endo announced Thursday.

FDA concerns about the safety of two testosterone boosters from Endo Pharmaceuticals may delay their approval, but safety concerns haven't kept testosterone sales from increasing 25 percent in the past year , according Business Week .

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference , today announced that Noah D. Beerman has joined the company as its new President and Chief Executive Officer.

Bioniche Life Sciences Inc.'s first-quarter loss more than doubled as revenues slightly dipped, the biotechnology company said Friday.

Bioniche Life Sciences Inc. , a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

Penwest Pharmaceuticals Co. November 5, 2009 11:00 am ET Executives Jennifer Good - President and CEO Frank Muscolo - Corporate Controller and Chief Accounting Officer Analysts David Watson Scott Henry - Roth Capital Presentation Operator At this time, I would like to welcome everyone to the Penwest third quarter 2009 financial results conference ...

BUYINS.NET, www.buyins.net, a provider of unique trading technologies, released a report on October 27, 2009 at 10:32 am PDT stating that Endo Pharmaceuticals was expected to be higher after its earnings were released before the open on Thursday, October 29, 2009.

When Endo Pharmaceuticals acquired two experimental testosterone products earlier this year, CEO David P. Holveck predicted that safety issues might delay approval by the U.S. Food & Drug Administration.

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application for Fortesta 2% Gel for men diagnosed with low testosterone , also known as hypogonadism.

Shares in ProStrakan, the Borders-based speciality pharmaceutical group, plunged almost 5% yesterday after it emerged US health regulators delayed approval of its cure-all for the male menopause.

Endo Pharmaceuticals said Monday it expects to respond to the Food and Drug Administration's questions about the company's new drug application for the low testosterone treatment Fortesta by mid-2010. Fortesta is an experimental gel product for men diagnosed with low testosterone, also known as hypogonadism.